| Species |
Human |
| Protein Construction |
RGM-C (Gln36-Asp400)_x000D_
Accession # Q6ZVN8-1 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized RGM-C, His, Human at 1μg/ml (100μl/well) on the plate can bind AntiRGMC Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
40 kDa (mature), 26 kDa (C-terminus peptide) and 14 kDa (N-terminus peptide) |
| Apparent Molecular Weight |
Due to enzyme lysis and glycosylation, the protein migrates to 55-60 kDa, 30-40 kDa, 20-25 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
RGM gene family ('Repulsive Axonal Guidance molecules' A, B and C),both RGM A and B are mostly expressed in central nervous system, while RGM C is exclusively expressed in all striated muscle and in the myocardium. RGM A and B appear at every level of the developing neural axis, where they colocalize to a large extent in the mantle layer, although only RGM A appears in the neuroepithelium, and only RGM B in the peripheral nervous system. |
| Synonyms |
Hemojuvelin; Rgmc; DL-M; HFE2; HFE2AMGC23953; HJV; JH; RGMC; RGM-C |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
